?Klotho is identified as a target for theranostics in non-small cell lung cancer.

ABSTRACT: Non-small cell lung cancer (NSCLC) remains a great challenge, calling for the identification of novel molecular targets with diagnostic/therapeutic value. Here, we sought to characterize the expression of ?Klotho and its anti-tumor roles in NSCLC. Methods: The expression of ?Klotho was examined in NSCLC cells and tissues by western blot, qRT-PCR and immunohistochemistry staining respectively. Biological roles of ?Klotho were revealed by a series of functional in vitro and in vivo studies. Serum ?Klotho concentrations of patients were measured using specific ELISA methods. Results: Serum ?Klotho concentrations of NSCLC patients were significantly lower than the control group. Moreover, ?Klotho expression was negatively associated with lymph node metastasis, overall survival and progression-free survival. Overexpression of ?Klotho or exogenous ?Klotho administration inhibited the proliferation and migration of NSCLC cells, accompanied by induction of apoptosis, G1 to S phase arrest, and inactivation of ERK1/2, AKT and STAT3 signaling. Furthermore, ?Klotho overexpression inhibited NSCLC tumor growth in vivo. Conclusions: ?Klotho serves as a novel target for theranostics in NSCLC, which has potential clinical applications in the future.

SUBMITTER: Li F 

PROVIDER: S-EPMC6831461 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature